Novo Nordisk to Book $820M Impairment Loss as it Halts Clarion-CKD Trial
$Novo-Nordisk A/S(NVO.US$ said it decided to stop its CLARION-CKD phase 3 trial and will book an impairment loss of 5.7 billion Danish kroner ($820 million) in the second quarter after the clinical study failed to meet its primary goal.
The phase 3 CLARION-CKD trial, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease, was conducted by KBP Biosciences, a company acquired by Novo Nordisk in 2023.
In a filing with the Securities and Exchange Commission, the company said the impairment loss corresponds to an estimated negative impact of about 6 percentage points on operating profit growth outlook at CER for 2024 that Novo Nordisk provided earlier.
The company will file its financial results for the first six months of 2024 and its financial outlook for the full year on Aug. 7, according to the filing.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Moomoo Senior News and Community Manager
Former editor at Bloomberg, then Lazard Asset Management. Posts aren’t investment advice. Views are just mine.
3122Followers
12Following
7381Visitors
Follow